Novel hearing therapeutics are rapidly progressing along the innovation pathway and into
the clinical trial domain. Because these trials are new to the hearing community, they come …

Most of episodic or progressive syndromes show familial clustering. A detailed phenotyping
with a complete familial history of vestibular symptoms is required to conduct a genetic …

Inner ear gene therapy offers great promise as a potential treatment for hearing loss and
dizziness. One of the critical determinants of the success of inner ear gene therapy is to find …

Over 450 million people worldwide suffer from hearing loss, leading to an estimated
economic burden of∼ $750 billion. The past decade has seen significant advances in the …

Precision medicine (PM) proposes customized medical care based on a patient's unique
genome, biomarkers, environment and behaviors. Hearing loss (HL) is the most common …

Neonatal gene therapy has been shown to prevent inner ear dysfunction in mouse models
of Usher syndrome type I (USH1), the most common genetic cause of combined deafness …

Auditory neuropathy is caused by the loss of afferent input to the brainstem via the
components of the neural pathway comprising inner hair cells and the first order neurons of …

Targeting specific cell types in the mammalian inner ear is important for treating genetic
hearing loss due to the different cell type-specific functions. Adeno-associated virus (AAV) is …

Outcomes with contemporary cochlear implants (CI) depend partly upon the survival and
condition of the cochlear spiral ganglion (SG) neurons. Previous studies indicate that CI …

Sensorineural hearing loss is one of the most common sensory disorders worldwide. Recent
advances in vector design have paved the way for investigations into the use of adeno …